Synergistic anti-leukemic interactions between AT9283, a multi-targeted TKI that inhibits Bcr-Abl, FLT3, JAK and aurora kinases [86,87,88], and entinostat have been observed in Bcr-Abl+ cells, including those bearing the gatekeeper mutation T315I, as well as in AML cells, both FLT3-mutated and -wild type (Nguyen and Grant, unpublished observations). This evidence concerns the gene FLT3 and acute myeloid leukemia.